HemaSphere (Jun 2022)
P383: USING CF-DNA AS STARTING MATERIAL FOR MRD STUDIES BY NGS IMPROVES THE SENSITIVITY OF THE METHOD AGAINST CTCS.
- N. Álvarez Sánchez-Redondo,
- S. Dorado,
- A. Martín,
- L. Rufián,
- V. Garrido,
- A. Giménez,
- L. Moreno,
- Y. Heredia,
- J. Martínez-López,
- S. Barrio,
- R. Ayala
Affiliations
- N. Álvarez Sánchez-Redondo
- 1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC
- S. Dorado
- 2 3.Computer Science and 4.Altum Sequencing Co., Madrid, Spain. Engineering Department. Carlos III University, Madrid and
- A. Martín
- 3 4.Altum Sequencing Co., Madrid, Spain.
- L. Rufián
- 1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC
- V. Garrido
- 1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC
- A. Giménez
- 1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC
- L. Moreno
- 1 1. Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC
- Y. Heredia
- 4 4. Altum Sequencing Co., Madrid, Spain.
- J. Martínez-López
- 5 1.Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, and 2.Complutense University of Madrid
- S. Barrio
- 6 1.Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, and 4.Altum Sequencing Co., Madrid, Spain.
- R. Ayala
- 7 1.Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, and 2.Complutense University of Madrid., Madrid, Spain
- DOI
- https://doi.org/10.1097/01.HS9.0000844420.94019.1a
- Journal volume & issue
-
Vol. 6
pp. 283 – 284
Abstract
No abstracts available.